Eyepoint Pharmac Stock Price, News & Analysis

EyePoint Pharmaceuticals (NASDAQ: EYPT), a retinal disease therapeutics company, announced the granting of inducement stock options to seven new employees on July 15, 2025. The awards, issued outside the company's 2023 Long-Term Incentive Plan, total 63,900 shares with an exercise price of $9.84 per share.

The options have a ten-year term and follow a four-year vesting schedule, with 25% vesting after the first year and the remainder vesting monthly over three years, contingent on continued employment.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to three new employees as inducement awards. The grants, approved by the Compensation Committee, include options to purchase up to 12,500 shares of EyePoint common stock at an exercise price of $9.03 per share, which was the closing price on June 13, 2025. These options have a ten-year term and follow a four-year vesting schedule, with 25% vesting after the first year and the remainder vesting monthly over the following three years. The inducement awards were made outside the Company's 2023 Long-Term Incentive Plan in compliance with NASDAQ Listing Rule 5635(c)(4).

EyePoint Pharmaceuticals (NASDAQ: EYPT), a company focused on developing therapeutics for serious retinal diseases, has announced its participation in three upcoming investor conferences in June 2025:

• Jefferies Global Healthcare Conference on June 4 at 1:25 p.m. ET
• Goldman Sachs 46th Annual Global Healthcare Conference on June 10 at 2:40 p.m. ET
• Guggenheim BioFrontier Boston Event on June 25 at 4:00 p.m. ET

The company will participate in fireside chats at each event, with live webcasts and archived replays available through EyePoint's investor relations website.

EyePoint Pharmaceuticals (EYPT) has completed enrollment in its Phase 3 LUGANO trial for DURAVYU™, a potential treatment for wet age-related macular degeneration (wet AMD). The trial enrolled over 400 patients in just seven months, marking one of the fastest enrollments for a wet AMD Phase 3 trial. The company's second pivotal trial, LUCIA, has reached 60% enrollment and is expected to complete in Q3 2025. Topline data from LUGANO is anticipated in mid-2026, with LUCIA results following in H2 2026. DURAVYU aims to be the first sustained-release tyrosine kinase inhibitor for wet AMD, offering 6-month redosing intervals. The trials will evaluate DURAVYU's efficacy against aflibercept, focusing on changes in best corrected visual acuity as the primary endpoint.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to seven new employees as inducement awards. The grants, approved by the Compensation Committee on May 15, 2025, include options to purchase up to 136,700 shares of EyePoint common stock at an exercise price of $5.72 per share. These options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments over the following three years. The inducement awards were granted outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

EyePoint Pharmaceuticals (NASDAQ: EYPT), a pharmaceutical company focused on developing treatments for serious retinal diseases, has announced its participation in three upcoming investor conferences in May 2025:

- RBC Capital Markets Global Healthcare Conference: Fireside chat on May 20 at 10:00 a.m. ET
- Mizuho Neuro & Ophthalmology Summit: One-on-one meetings on May 21
- Stifel Virtual Ophthalmology Forum: Fireside chat on May 27 at 8:30 a.m. ET

Investors can access live webcasts and replays of the presentations through EyePoint's website investor section.

EyePoint Pharmaceuticals (EYPT) reported strong progress in Q1 2025, with their Phase 3 DURAVYU trials for wet AMD showing exceptional enrollment rates. The LUGANO trial has reached over 90% enrollment and LUCIA over 50%, with both expected to complete enrollment in 2H 2025. The company reported total net revenue of $24.5 million, up from $11.7 million in Q1 2024, primarily driven by YUTIQ licensing revenue.

The company maintains a strong financial position with $318.2 million in cash and equivalents, providing runway into 2027. Operating expenses increased to $73.3 million, mainly due to accelerated trial enrollment. Net loss was $45.2 million ($0.65 per share). DURAVYU demonstrated promising results in Phase 2 VERONA trial for diabetic macular edema, showing significant vision improvement and fluid reduction compared to aflibercept control.

EyePoint Pharmaceuticals (NASDAQ: EYPT), a pharmaceutical company focused on developing innovative therapeutics for serious retinal diseases, has scheduled its first quarter 2025 financial results announcement for May 7, 2025.

The company will host a conference call and live webcast at 8:30 a.m. ET to discuss Q1 2025 financial performance and recent corporate developments. Interested participants can register for the audio conference through a provided link, while a live webcast will be accessible through the Investors section of EyePoint's website. A replay of the webcast will be made available on the corporate website after the call concludes.

EyePoint Pharmaceuticals (EYPT) has granted non-statutory stock options to four new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The grants, approved by the Compensation Committee on April 15, 2025, allow the purchase of up to 65,000 shares of EyePoint common stock at an exercise price of $5.67 per share.

The options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first anniversary, with the remaining shares vesting in equal monthly installments over the following three years. Vesting is contingent upon continued employment with EyePoint through the applicable dates.